HCG18 and hepatocellular carcinoma: Besides, HCG18 was involved in the responsiveness of HCCs to sorafenib treatment, and knockdown of HCG18 can promote the sensitivity of HCC cells to sorafenib, inferring that targeting HCG18 might be an effective strategy to overcome sorafenib resistance in HCC 51.